Establishment Labs (ESTA) reported $211M in revenue for fiscal 2025, +27.1% year on year. That ranks #2645 by revenue among 2853 SEC filers and #282 in Healthcare. It posted a net loss of −$51.1M for the same year. Revenue has grown 25.3% a year on average since 2017 ($34.7M then). The fiscal 2025 balance sheet shows $357M in total assets, $75.6M in cash and $248M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $211M | +27.1% | FY20252025-12-31 |
| Gross profitGrossProfit | $146M | +33.6% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$39.0M | +$11.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$51.1M | +$33.5M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$50.9M | +$7.6M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $6.0M | −1.1% | FY20252025-12-31 |
| Total assetsAssets | $357M | +3.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $23.5M | −55.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $75.6M | −16.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $248M | +12.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $59.9M | −$13.4M | Open → |
| Q2 20262026-06-30 | $67.5M | −$11.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Establishment Labs Holdings Inc.
- Ticker
- ESTA
- Exchange
- Nasdaq
- SIC classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- Fiscal year end
- 12-31
- CIK
- 0001688757
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Vanda PharmaceuticalsVNDA | $216M | −$221M |
| AmarinAMRN | $214M | −$38.8M |
| Treace Medical ConceptsTMCI | $213M | −$59.0M |
| Establishment LabsESTA | $211M | −$51.1M |
| Canopy GrowthCGC | $204M | −$189M |
| Si-BoneSIBN | $201M | −$18.9M |
| ValnevaVALN | $197M | −$130M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Establishment Labs — Key figures |url=https://companiesranked.com/en/company/establishment-labs |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Establishment Labs — Key figures. CompaniesRanked. https://companiesranked.com/en/company/establishment-labsBibTeX
@misc{companiesranked-en-company-establishment-labs-2026,
author = {{CompaniesRanked}},
title = {{Establishment Labs — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/establishment-labs}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001688757-26-000022 · February 27, 2026
{{cite web |title=Establishment Labs — Key figures — 10-K (0001688757-26-000022) |url=https://www.sec.gov/Archives/edgar/data/1688757/000168875726000022/esta-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.